scholarly journals Systemic Lupus Erythematosus with Crohn’s Disease: A Rare Combination and Unusual Presentation

2021 ◽  
Author(s):  
Abdulrahman Algassim ◽  
Naif Alghonaim ◽  
Ibrahim Alruzug ◽  
Mohamed S Elbayoumy ◽  
Azza Atallah
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Tumour Necrosis Factor ◽  
Lupus Erythematosus ◽  
Tumour Necrosis ◽  
Unusual Presentation ◽  
Systemic Lupus ◽  
Rare Combination ◽  
Necrosis Factor

The coexistence of systemic lupus erythematosus (SLE) and Crohn’s disease (CD) is very rare. The usual sequence of occurrence is CD followed by SLE, where CD treatment with anti-tumour necrosis factor (anti-TNF) induces the latter. Here, we present a case of this rare combination but with sequence reversal. The patient was unresponsive to steroids and we achieved remission with infliximab.

scholarly journals Increased Frequency of the Uncommon Allele of a Tumour Necrosis Factor Alpha Gene Polymorphism in Rheumatoid Arthritis and Systemic Lupus Erythematosus

1994 ◽  
Vol 12 (2) ◽  
pp. 127-133 ◽  
Author(s):  
Victor A. Danis ◽  
Michelle Millington ◽  
Valentine Hyland ◽  
Ron Lawford ◽  
Qirong Huang ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Systemic Lupus Erythematosus ◽  
Tumour Necrosis Factor ◽  
Lupus Erythematosus ◽  
Tumour Necrosis ◽  
Tumour Necrosis Factor Alpha ◽  
Systemic Lupus ◽  
Necrosis Factor Alpha ◽  
Factor Alpha ◽  
Necrosis Factor

The frequency of the uncommon allele (TNF2) of a polymorphism in the promoter region of the tumour necrosis factor alpha (TN Fα) gene in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) was found to be 3 times that of the normal anglo-saxon population. In SLE patients, this allele was strongly associated with HLA-DR3 expression and was also more frequent in patients who did not have malar rash. Functional studies of normal monocyte cytokine production in vitro showed that this genotype was associated with increased IL-1α protein production but there were no differences in the production of TNFα protein.

Urinary B-cell-activating factor of the tumour necrosis factor family (BAFF) in systemic lupus erythematosus

Lupus ◽  
2018 ◽  
Vol 27 (13) ◽  
pp. 2029-2040 ◽  
Author(s):  
F B Vincent ◽  
R Kandane-Rathnayake ◽  
A Y Hoi ◽  
L Slavin ◽  
J D Godsell ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Renal Disease ◽  
Disease Activity ◽  
B Cell ◽  
Tumour Necrosis Factor ◽  
Lupus Erythematosus ◽  
Tumour Necrosis ◽  
Systemic Lupus ◽  
B Cell Activating Factor ◽  
Necrosis Factor

Introduction We examined the clinical relevance of urinary concentrations of B-cell–activating factor of the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) in systemic lupus erythematosus (SLE). Methods We quantified urinary BAFF (uBAFF) by enzyme-linked immunosorbent assay in 85 SLE, 28 primary Sjögren syndrome (pSS), 40 immunoglobulin A nephropathy (IgAN) patients and 36 healthy controls (HCs). Urinary APRIL (uAPRIL) and monocyte chemoattractant protein 1 (uMCP-1) were also quantified. Overall and renal SLE disease activity were assessed using the Systemic Lupus Erythematosus Disease Activity Index 2000. Results uBAFF was detected in 12% (10/85) of SLE patients, but was undetectable in HCs, IgAN and pSS patients. uBAFF was detectable in 28% (5/18) of SLE patients with active nephritis vs 5/67 (7%) of those without ( p = 0.03), and uBAFF was significantly higher in active renal patients ( p = 0.02) and more likely to be detected in patients with persistently active renal disease. In comparison, uAPRIL and uMCP-1 were detected in 32% (25/77) and 46% (22/48) of SLE patients, respectively. While no difference in proportion of samples with detectable uAPRIL was observed between SLE, HCs and IgAN patients, both uAPRIL and uMCP-1 were significantly detectable in higher proportions of patients with active renal disease. Conclusions uBAFF was detectable in a small but a significant proportion of SLE patients but not in other groups tested, and was higher in SLE patients with active renal disease.

Sign in / Sign up

Export Citation Format

Share Document